CYTK - CYTOKINETICS INC
IEX Last Trade
48.59
-7.300 -15.024%
Share volume: 0
Last Updated: Tue 24 Dec 2024 06:00:00 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
35.29%
PREVIOUS CLOSE
CHG
CHG%
$55.89
-7.30
-13.06%
Fundamental analysis
29%
Profitability
25%
Dept financing
25%
Liquidity
75%
Performance
21%
Performance
5 Days
-0.70%
1 Month
-3.42%
3 Months
-7.88%
6 Months
-8.21%
1 Year
8.81%
2 Year
7.39%
Key data
Stock price
$48.59
DAY RANGE
$49.02 - $55.89
52 WEEK RANGE
$47.30 - $110.25
52 WEEK CHANGE
-$41.84
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: Robert I. Blum
Region: US
Website: cytokinetics.com
Employees: 250
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: cytokinetics.com
Employees: 250
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Cytokinetics, Incorporated focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure.
Recent news